A Mobile Lifestyle Management Program (GlycoLeap) for People With Type 2 Diabetes: Single-Arm Feasibility Study (Preprint)

David Koot, P. Goh, Robyn Su May Lim, Yubing Tian, Teng Yan Yau, Ngiap Chuan Tan, Eric Finkelstein2018 · DOI

TL;DR

This study investigated the feasibility and potential effectiveness of GlycoLeap, a mobile lifestyle management program for Type 2 Diabetes (T2DM) patients. The program, combining online lessons and a smartphone app with health coaching, showed promising results in improving HbA1c levels and weight, suggesting its potential as a scalable intervention for T2DM management.

What Problem Does This Paper Address?

Type 2 Diabetes Mellitus (T2DM) is a growing global health concern, with Singapore facing a particularly high prevalence. While lifestyle modifications are crucial for managing T2DM and preventing complications, traditional interventions are often resource-intensive and difficult to implement in primary care settings. This paper addresses the challenge of delivering effective, accessible, and scalable lifestyle management solutions for T2DM patients by exploring the potential of mobile health (mHealth) applications. GlycoLeap aims to bridge this gap by offering a low-cost, adaptable platform that integrates educational content, self-monitoring tools, and personalized health coaching.

Methods

This was a single-arm feasibility study employing the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework to evaluate the GlycoLeap program.

  • Reach: Assessed by the percentage of patients who consented to participate out of all those approached.
  • Effectiveness: Measured by changes in HbA1c (primary outcome) and weight (secondary outcome) from baseline to follow-up. Both intention-to-treat (ITT) and per-protocol analyses were conducted.
  • Implementation: Evaluated through various participatory metrics reflecting program engagement, such as the number of online lessons completed, blood glucose logs, weight logs, meal logs, and messages sent to health coaches.
  • Maintenance: Assessed via post-intervention user satisfaction surveys, including ease of use, perceived usefulness, overall rating, and likelihood of recommendation, to gauge the program's sustainability.

The study recruited 100 T2DM patients with HbA1c levels of ≥7.5% from a single community healthcare facility. Participants received a 6-month GlycoLeap program and were assessed at baseline and at a follow-up of at least 12 weeks.

Datasets

Not discussed in the paper. The study utilized data collected directly from the 100 participants enrolled in the GlycoLeap program.

Key Insights and Ideas

  • The RE-AIM Framework is a valuable tool for evaluating mHealth interventions: By systematically assessing Reach, Effectiveness, Implementation, and Maintenance, the study provides a comprehensive understanding of the program's potential beyond just clinical outcomes.
  • Engagement wanes over time, but clinical benefits persist: While participants' engagement with various program components decreased after the initial weeks, significant improvements in HbA1c were still observed. This highlights the challenge of sustained engagement in digital health interventions and the need for strategies to maintain user motivation.
  • Mobile health can be a viable strategy for diabetes education and behavior change: Despite lower-than-ideal lesson completion rates, self-reported increases in blood glucose monitoring and dietary improvements suggest that GlycoLeap can effectively influence patient behavior.
  • The "Reach" metric needs careful interpretation for mHealth: The study's low initial reach (13.2%) was influenced by eligibility criteria (e.g., smartphone ownership, English proficiency) that might not reflect broader interest if the program were more accessible.

Key Results

  • Reach: 13.2% of the 785 approached patients consented to participate.
  • Effectiveness:
    • HbA1c levels decreased by an average of 1.3 percentage points (P<.001) in the per-protocol analysis.
  • 59% of participants achieved a ≥1 percentage point reduction in HbA1c.
  • Weight loss averaged 2.3 kg (P<.001).
  • 21% of participants lost ≥5% of their initial body weight.
  • Greater weight logging frequency was associated with larger HbA1c reductions (P=.007).
  • Implementation: Program engagement was high initially but decreased over time. Participants reported monitoring blood glucose on more days and made positive dietary changes due to app engagement.
  • Maintenance: User satisfaction was high, with 74% rating the app "good/very good" and 79% willing to recommend it. 21% expressed willingness to pay a modest annual fee for continued access.

Limitations and Future Work

  • Limitations:
    • Single-arm design: The study lacked a control group, making it difficult to definitively attribute improvements solely to GlycoLeap, as other factors could have contributed.
  • Short follow-up period: The ≥12-week follow-up might not capture long-term effectiveness or maintenance of benefits.
  • Potential for bias: Self-reported data for engagement and lifestyle changes are subject to recall bias.
  • Future Work:
    • The authors strongly recommend a randomized controlled trial (RCT) of at least 12 months to rigorously evaluate the effectiveness and cost-effectiveness of GlycoLeap.
  • Further research should explore strategies to improve and sustain user engagement throughout the intervention period.
  • Investigating the impact of GlycoLeap in other languages and with increasing smartphone penetration is also suggested.

Summary updated

Abstract

<sec> <title>BACKGROUND</title> Singapore’s current prevalence of diabetes exceeds 13.6%. Although lifestyle modification can be effective for reducing the risks for complications of type 2 diabetes mellitus (T2DM), traditional lifestyle interventions are often difficult to administer in the primary care setting due to limited resources. Mobile health apps can address these limitations by offering low-cost, adaptable, and accessible platforms for disseminating lifestyle management interventions. </sec> <sec> <title>OBJECTIVE</title> Using the RE-AIM evaluation framework, this study assessed the potential effectiveness and feasibility of GlycoLeap, a mobile lifestyle management program for people with T2DM, as an add-on to standard care. </sec> <sec> <title>METHODS</title> This single-arm feasibility study recruited 100 patients with T2DM and glycated hemoglobin (HbA1c) levels of ≥7.5% from a single community health care facility in Singapore. All participants were given access to a 6-month mobile lifestyle management program, GlycoLeap, comprising online lessons and the Glyco mobile phone app with a health coaching feature. The GlycoLeap program was evaluated using 4 relevant dimensions of the RE-AIM framework: (1) reach (percentage who consented to participate out of all patients approached), (2) effectiveness (percentage point change in HbA1c [primary outcome] and weight loss [secondary outcome]), (3) implementation (program engagement as assessed by various participatory metrics), and (4) maintenance (postintervention user satisfaction surveys to predict the sustainability of GlycoLeap). Participants were assessed at baseline and at follow-up (≥12 weeks after starting the intervention). </sec> <sec> <title>RESULTS</title> A total of 785 patients were approached of whom 104 consented to participate, placing the reach at 13.2%. Four were excluded after eligibility screening, and 100 patients were recruited. Program engagement (implementation) started out high but decreased with time for all evaluated components. Self-reported survey data suggest that participants monitored their blood glucose on more days in the past week at follow-up compared to baseline (P&lt;.001) and reported positive changes to their diet due to app engagement (P&lt;.001) (implementation). Primary outcome data were available for 83 participants. Statistically significant improvements were observed for HbA1c (–1.3 percentage points, P&lt;.001) with greater improvements for those who logged their weight more often (P=.007) (effectiveness). Participants also had a 2.3% reduction in baseline weight (P&lt;.001) (effectiveness). User satisfaction was high with 74% (59/80) and 79% (63/80) of participants rating the app good or very good and claiming that they would probably or definitely recommend the app to others, respectively (maintenance). </sec> <sec> <title>CONCLUSIONS</title> Although measures of program engagement decreased with time, clinically significant improvements in HbA1c were achieved with the potential for broader implementation. However, we cannot rule out that these improvements were due to factors unrelated to GlycoLeap. Therefore, we would recommend evaluating the effectiveness and cost effectiveness of GlycoLeap using a randomized controlled trial of at least 12 months. </sec> <sec> <title>CLINICALTRIAL</title> ClinicalTrials.gov NCT03091517; https://clinicaltrials.gov/ct2/show/NCT03091517 (Archived by WebCite at http://www.webcitation.org/77rNqhwRn) </sec>
BibTeX
@misc{koot2018mobile,
  author = {David Koot and P. Goh and Robyn Su May Lim and Yubing Tian and Teng Yan Yau and Ngiap Chuan Tan and Eric Finkelstein},
  title = {{A Mobile Lifestyle Management Program (GlycoLeap) for People With Type 2 Diabetes: Single-Arm Feasibility Study (Preprint)}},
  year = {2018},
  doi = {10.2196/preprints.12965},
}
Figure